Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein

The Rationale of Retinal Endovascular Fibrinolysis in the Treatment of Retinal Vein Occlusion

“…[22][23][24][25] However, the selection of the patients plays an important role, especially because the evolution of CRVO may sometimes be favorable despite the lack of any intervention. 27 The absence of randomized controlled trials and the lack of a longterm follow-up in the existing trials are important drawbacks in evaluating the clinical efficacy of REF.…”

“…21 Preliminary results showed safe visual recovery. [22][23][24][25] Nevertheless, other investigators could not replicate these good results and considered the technique to be too sophisticated 26 or even lacking a scientific rationale. 27 In the current study, we describe a technique of REF in an experimental RVO model using a simple micropipette for retinal vein puncture and microinjection.…”

Measurement of PO2 during vitrectomy for central retinal vein occlusion, a pilot study

“…Several treatments have been proposed including injections of recombinant tissue plasminogen activator into the vitreous or direct injection into a cannulated central vein 5 . The main surgical procedure over recent years has been radial optic neurotomy (RON) 6,7 , thought to be effective by improving central retinal vein blood flow by relieving pressure on the vein as it exits the lamina cribrosa.…”

Intravitreal Injection of Tissue Plasminogen Activator for Central Retinal Vein Occlusion.

“…To limit the systemic side effects, investigators have used other approaches to deliver the thrombolytic agent locally, such as intravitreal injection and intravenous retinal cannulization. [13][14][15] Lahey and associates 14 and Glacet-Bernard and colleagues 15 first reported on the intravitreal injection of tissue plasminogen activator (tPA) for CRVO. This pilot study was designed to evaluate the effects of intravitreal injection of tPA in eyes with acute CRVO.…”